Beautiful Virgin Islands

Tuesday, Jul 01, 2025

Cuba reports 92.4 percent efficacy for 3 dose SOBERANA 02 COVID-19 vaccine

Cuba reports 92.4 percent efficacy for 3 dose SOBERANA 02 COVID-19 vaccine

A new study describes the results of the safety and efficacy phase trials of a new COVID-19 vaccine from Cuba.

Study findings
Vaccines are a high-priority public health intervention; however, the success of the vaccination program depends on the speed and coverage of the rollout.

SOBERANA 02 is the first conjugated vaccine to be developed against SARS-CoV-2. The vaccine uses the recombinant receptor-binding domain (RBD) of the viral spike protein, chemically attached to the tetanus toxoid antigen in a molar ratio of 6:1 and adsorbed on 500 micrograms (µg) of alumina. Conversely, SOBERANA Plus contains dimeric RBD 50 µg, adsorbed on 1,250 µg alumina, having been developed as a “universal booster.”

With this, SOBERANA 02 joins other conjugated vaccines, such as the protein-polysaccharide conjugated vaccine against Hemophilus influenzae type b, Neisseria meningitidis, and Streptococcus pneumoniae.

With the current experimental vaccine, two doses have been found to elicit neutralizing antibodies, along with both memory B- and T-cells, secreting interferon-gamma (IFN-γ) as well as showing a T-helper cell type 1 (Th1) profile of immunity.

This vaccine could also be used as a heterologous third booster dose to enhance the level of neutralizing anti-RBD antibodies. Following successful Phase 1 and 2a trials, the Phase 3 trial was launched to assess the efficacy and safety profile of two usage patterns of SOBERANA, which include a two-dose regimen of SOBERANA 02, and evaluate this regimen when combined with the third dose of SOBERANA Plus.

The participants of the current study were all healthy adults from different parts of Havana, Cuba. Each participant was assigned in a randomized double-blinded placebo-controlled manner to vaccine and control groups. The mean age was 48 years, with an almost equal number of males and females.

One group (A) received the two-dose homologous regimen, the second (group B) the heterologous three-dose regimen, and the third (group C) the placebo. None of the final participants had confirmed SARS-CoV-2 infection at any point.

There were 0.8 COVID-19 cases per 1,000 person-years (PY) in group A, and 2.7 in the placebo, corresponding to 198 and 155 cases, respectively, indicating a two-dose vaccine efficacy (VE) of 71% compared to placebo.

With the heterologous three-dose regimen, the VE was greater than 92% relative to the placebo, at an incidence of 0.1 per 1,000 PY in group B (170 vs 155 cases in groups B and C, respectively).

Protection against severe COVID-19 was 63% in group A and 100% for group B. Comparatively, when considering deaths due to COVID-19, VE was 59% and 100%, respectively.

Implications
The current study shows the SOBERANA 02 conjugate vaccine to be safe and effective in preventing severe COVID-19 in adults up to 80 years of age. A VE of over 60% was expected during the period when the ancestral SARS-CoV-2 strain was circulating. However, a VE of 62% was achieved, even during a period when the dominant strain was the Beta SARS-CoV-2 variant of concern (VOC).

The SARS-CoV-2 Beta strain made up 74% of isolated sequences at the time in Havana. The high VE was observed in spite of the presence of the E484K mutation that confers resistance to neutralizing antibodies in the sera of individuals who have been immunized by natural infection or by vaccination.

By the time the final analysis was conducted, the Delta VOC was the dominant circulating strain; however, the VE at two doses was 71% at this time. The heterologous three-dose regimen led to VE exceeding 92%, but it still remained high irrespective of VOCs in circulation.

Even at the two-month mark, the safety profile was impressive, with mild transient local reactions and no serious adverse reactions reported. The third dose of the vaccine had few side effects.

The final VE comes from the figures compiled 14 days after the last immunization, or 70 days after the first dose with the triple-dose regimen. While this vaccine apparently offered protection against the Beta and Delta VOCs, further work is essential to assess the durability of immunity and the VE for the circulating VOCs.

* Important notice
medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information
Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
Robots Compete in Football Tournament in China Amid Injuries
Trump Administration Considers Withdrawal of Funding for Hospitals Providing Gender Treatment to Minors
Texas Enacts Law Allowing Gold and Silver Transactions
China Unveils Miniature Insect-Like Surveillance Drone
OpenAI Secures Multimillion-Dollar AI Contracts with Pentagon, India, and Grab
Marc Marquez Claims Victory at Dutch Grand Prix Amidst Family Misfortune
Germany Votes to Suspend Family Reunification for Asylum Seekers
Elon Musk Critiques Senate Budget Proposal Over Job Losses and Strategic Risks
Los Angeles Riots ended with Federal Investigations into Funding
Budapest Pride Parade Draws 200,000 Participants Amid Government Ban
Southern Europe Experiences Extreme Heat
Xiaomi's YU7 SUV Launch Garners Record Pre-Orders Amid Market Challenges
Jeff Bezos and Lauren Sanchez's Lavish Wedding in Venice
Russia Launches Largest Air Assault on Ukraine Since Invasion
Education Secretary Announces Overhaul of Complaints System Amid Rising Parental Grievances
Massive Anti-Government Protests Erupt in Belgrade
Trump Ends Trade Talks with Canada Over Digital Services Tax
UK Government Softens Welfare Reform Plans Amid Labour Party Rebellion
Labour Faces Rebellion Over Disability Benefit Reforms Ahead of Key Vote
Jeff Bezos and Lauren Sánchez Host Lavish Wedding in Venice Amid Protests
Trump Asserts Readiness for Further Strikes on Iran Amid Nuclear Tensions
North Korea to Open New Beach Resort to Boost Tourism Economy
UK Labour Party Faces Internal Tensions Over Welfare Reforms
Andrew Cuomo Hints at Potential November Comeback Amid Democratic Primary Results
Curtis Sliwa Champions His Vision for New York City Amid Rising Crime Concerns
Federal Reserve Proposes Changes to Capital Rule Affecting Major Banks
EU TO HUNGARY: LET THEM PRIDE OR PREP FOR SHADE. ORBÁN TO EU: STAY IN YOUR LANE AND FIX YOUR OWN MESS.
Trump Escalates Criticism of Media Over Iran Strike Coverage
Trump Announces Upcoming US-Iran Meeting Amid Controversial Airstrikes
Trump Moves to Reshape Middle East Following Israel-Iran Conflict
Big Four Accounting Firms Fined in Exam Cheating Scandal
NATO Members Agree to 5% Defense Spending Target by 2035
Australia's Star Casino Secures $195 Million Rescue Package Amid Challenges
UK to Enhance Nuclear Capabilities with Acquisition of F-35A Fighter Jets
Russian Shadow Payments via Cryptocurrency Reach $9 Billion
Explosions Rock Doha as Iranian Missiles Target Qatar
“You Have 12 Hours to Flee”: Israeli Threat Campaign Targets Surviving Iranian Officials
Macron and Merz: Europe must arm itself in an unstable world
Germany and Italy Under Pressure to Repatriate $245bn of Gold from US Vaults
Airlines Evaluate Flight Cancellations Amid Escalating US-Iran Tensions
Starmer Invites Innovators to Join Government Talent Scheme
UK Economy’s Strong Opening Quarter Shows Signs of Cooling
Harrods Seeks Court Order to Secure Al Fayed Estate for Victims
BA and Singapore Airlines Cancel Dubai Flights Amid Middle East Tensions
Trump Faces Backlash from MAGA Base Over Iran Strikes
Meta Bets $14 B on Alexandr Wang to Drive AI Ambitions
WATCH: Israeli forces show the aftermath of a massive airstrike at Iran's Isfahan nuclear site
FedEx Founder Fred Smith, ‘Heart and Soul’ of the Company, Dies at 80
Chinese Factories Shift Away from U.S. Amid Trump‑Era Tariffs
Pimco Seizes Opportunity in Japan’s Dislocated Bond Market
×